Skip to main content

Recording artist Glen Campbell in 2008: Campbell has been diagnosed with Alzheimer's disease.

PHIL McCARTEN/Reuters

Rhinestone Cowboy singer Glen Campbell says he is in the early stages of Alzheimer's disease and has recorded one last album as a farewell to his fans.

Campbell, 75, had been suffering from short-term memory loss for years, but the terminal Alzheimer's diagnosis only came six months ago, according to an interview published in People magazine on Wednesday.

"I still love making music," he was quoted as saying. "And I still love performing for my fans. I'd like to thank them for sticking with me through thick and thin."

Story continues below advertisement

Campbell's wife, Kim, said they decided to go public with his diagnosis ahead of a final concert tour this fall.

"Glen is still an awesome guitar player and singer," she said. "But if he flubs a lyric or gets confused on stage, I wouldn't want people to think, 'What's the matter with him? Is he drunk?'"

Campbell, who has been sober for years, returns to stores on Aug. 30 with Ghost on the Canvas, an album featuring original songs composed by the likes of Paul Westerberg of the Replacements and Jakob Dylan of the Wallflowers. Backing musicians include Chris Isaak, surf-guitarist Dick Dale and Smashing Pumpkins frontman Billy Corgan.

It marks a follow-up to 2008's wryly titled Meet Glen Campbell, in which he covered tunes by U2, Green Day, John Lennon and the Foo Fighters.

Campbell, who started out as a session guitarist for the Beach Boys and producer Phil Spector, rose to fame in the 1960s with such hits as Wichita Lineman and By the Time I Get to Phoenix. Perhaps his best-known song, Rhinestone Cowboy, was a No. 1 hit in 1975.

Report an error
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

Cannabis pro newsletter
To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies